News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
The programme will see participation from various ministries of the Government of India with the aim of 3Js – Jan Sandesh, Jan Bhagidari, and Jan Aandolan.
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Subscribe To Our Newsletter & Stay Updated
